Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cyclopharm Limited ( (AU:CYC) ) has shared an announcement.
Cyclopharm Limited has called its 2026 annual general meeting for 11.00 a.m. on 8 May at its Kingsgrove, NSW headquarters, setting out a detailed agenda and urging shareholders to vote either in person or via proxy. The meeting will cover standard items such as receiving financial statements, voting on the remuneration report, and the re-election of director Gregory King, alongside resolutions on ratifying a prior tranche of placement shares, approving a second tranche share issuance, providing a loan and amending share holding locks for the managing director, and renewing proportional takeover bid provisions, signalling ongoing capital management and governance adjustments that may affect shareholder rights and the company’s financing flexibility.
The most recent analyst rating on (AU:CYC) stock is a Sell with a A$0.68 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an Australian-listed company based in Kingsgrove, New South Wales. It operates in the healthcare sector, providing medical products and services, with its shareholder base engaged through regular governance and capital management activities such as annual general meetings and equity placements.
Average Trading Volume: 147,280
Technical Sentiment Signal: Sell
Current Market Cap: A$98.45M
Find detailed analytics on CYC stock on TipRanks’ Stock Analysis page.